Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC.LPTX · Entity 6392 | Chief Medical Officer | March 28, 2025 | April 01, 2025 |
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Chief Medical Officer | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYPHERPUNK TECHNOLOGIES INC.
Report date March 28, 2025 · Filed April 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,500 |
Reported balance
After 2025-03-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-28 · Exercise / conversion · Acquired 22,500 · Balance 27,500 F1: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs. F3: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock. F2: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-03-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-28 · Exercise / conversion · Disposed 22,500 · Balance 0 F3: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock. F1: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs. F4: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date. F5: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above. F6: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.
F2: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.
F3: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.
F4: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.
F5: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above.
F6: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.
Compass Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02 | Direct | 1,000,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). F2: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).
F2: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 16:33 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,000,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001171843-26-000061 · ownership.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: COMMON STOCK · 1,000,000 shares Expires 2036-01-02 F1 · shares: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). F2 · derivative.exercise_date: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 21:51 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-030804 · tm2511110-1_4seq1.xml · derivative · entry 2 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock. F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs. F4 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date. F5 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above. F6 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 21:51 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-030804 · tm2511110-1_4seq1.xml · nonDerivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs. F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock. F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 17:29 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-106347 · tm2425653-14_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:34 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001104659-24-009024 · tm244775-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-01-29 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 20:39 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-008419 · tm244628-3_4seq1.xml · derivative · entry 2 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit. F3 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 20:39 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008419 · tm244628-3_4seq1.xml · nonDerivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 16:30 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001104659-23-095366 · tm2324823-12_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-08-23 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on September 23, 2023 and an additional of such monthly installments vesting on the 23rd day of each calendar month thereafter. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001104659-23-041754 · tm2311741-14_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of March 31, 2023, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 21:27 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097620 · tm2225099-9_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:50 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011060 · tm225302-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:35 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074447 · tm2117938-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008995 · tm214605-4_4seq1.xml · derivative · entry 2 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008995 · tm214605-4_4seq1.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 21:19 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001104659-20-094203 · a4.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-08-09 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of August 10, 2020, the Vesting Start Date. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:22 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001104659-20-046080 · a4.xml · derivative · entry 1 Sirard Cynthia · CIK 0001808408 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-09 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 9, 2020, the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.